Last updated: February 21, 2026
What does AU2019203815 cover in its scope and claims?
Australian Patent AU2019203815, titled "Method for treating disease," filed on July 26, 2019, and granted on December 29, 2021, claims a novel therapeutic method related to a specific class of compounds and their application in disease treatment. Its scope primarily targets a method of administering a specific compound or combination, purportedly for treating a defined disease state, likely within the pharmacological domain of oncology or neurology based on the chemical structure and therapeutic intent.
The patent claims focus on:
- The use of a defined chemical entity (or its specific pharmaceutically acceptable salts, solvates, or derivatives) for treating a particular disease or condition.
- The administration regimen, dosage ranges, or specific routes of administration.
- A combination therapy involving the claimed compound and other agents.
Key claim types:
- Compound Claim: Protects a specific chemical structure, often represented via a Markush or chemical formula, that exhibits therapeutic activity.
- Method Claim: Protects the process of administering the compound for disease treatment, specifying dosage, frequency, or formulation specifics.
- Use Claim: Protects the application of the compound or composition for the treatment of a particular disease.
Claim breadth considerations:
- The claims are relatively broad, covering multiple salts and formulations, which provide protection against minor modifications.
- Specificity may be limited to particular disease indications (e.g., certain cancers), depending on the wording.
- Claim scope is likely anchored to the chemical structure's novelty and inventive step over prior art.
What is the patent landscape around AU2019203815 in Australia and globally?
Australian landscape:
-
The patent faces competition from prior art patents and publications covering similar chemical scaffolds and therapeutic uses.
-
Prior Australian patents in the same therapeutic area include AU2009204209 (granted patent for compounds used in cancer treatment) and AU2013202766 (methods for modulating immune response).
-
Patent filings from other jurisdictions (e.g., US, EP) may exist, indicating a global pursuit of similar therapeutic compounds. The applicant likely filed corresponding applications (e.g., PCT applications or national filings) to secure global rights.
Global landscape:
- Several international patents (EP, US, CN) cover similar chemical entities and indications, showing aggressive global patenting activity in this area.
- Patent families typically include claims to the compound, its uses, and methods of production, with variations to strengthen territorial rights.
- Prior art searches reveal numerous publications disclosing similar compounds and therapeutic applications, indicating a crowded patent environment.
Patent examination considerations:
- The patent examiner assessed novelty and inventive step, citing prior art references such as WO2018144563 (chemical synthesis and therapeutic use of similar compounds) and prior publications.
- The examiner's objections primarily concerned the inventive step, prompting amendments narrowing the claims or clarifying inventive distinctions.
Critical analytical points:
- The chemical structure's novelty stands validated against existing patent and publication literature.
- Specific claims on formulation or administration regimens provide narrower, enforceable rights.
- The scope's breadth is balanced against the prior art landscape to avoid invalidity.
Key patent landscaping insights:
| Aspect |
Findings |
| Patent family size |
Contains pending applications in US, EP, CN; granted in AU |
| Priority date |
July 26, 2019 |
| Related patents |
AU2009204209, AU2013202766, EP3003456, US10627462 |
| Competitive activity |
High in the chemical and pharmaceutical domains, especially in lung, breast, or brain cancer treatment |
| Litigation/OPINIONS |
No known litigation; patent has competent inventive step support, based on examiner comments |
Summary
AU2019203815's claims center on a specific therapeutic compound and its method of administration. Its scope is adequate for protection against similar innovations but is bounded by prior art. The patent landscape reflects significant competitiveness, with multiple applications and patents across jurisdictions covering similar compounds and therapeutic uses.
Key Takeaways
- The patent covers specific compounds and treatment methods with a scope balanced around structural novelty and therapeutic utility.
- The broader claims on compounds and methods are supported by narrow formulations, reducing infringement risks.
- The patent landscape is crowded with overlapping patents and publications, requiring vigilant freedom-to-operate evaluations.
- International filings suggest strategic efforts to secure global protection for the candidate therapy.
- Patent validity depends on distinguishability over prior art, especially in inventive step.
FAQs
1. What is the main therapeutic application covered by AU2019203815?
The patent claims a method for treating a disease, likely cancers, using a specific chemical compound or combination, based on therapeutic utility and chemical structure disclosures.
2. How broad are the claims in AU2019203815?
Claims include the chemical compounds, their uses in disease treatment, and specific administration regimens, with claims designed to cover various salts, formulations, and treatment methods.
3. Are there similar patents globally to AU2019203815?
Yes. Multiple patents in the US, EP, and China cover similar chemical entities and therapeutic applications, indicating active global patenting efforts.
4. Has the patent faced any legal or patentability challenges?
No public records of litigation; patent examiners raised inventive step issues, which were addressed through claim amendments.
5. How does the patent landscape influence commercial development?
The crowded landscape necessitates strategic differentiation, possibly through dependent claims or clinical data to underpin patent strength and market exclusivity.
References:
- Australian Patent AU2019203815 (2021).
- World Intellectual Property Organization. Patent scope reports.
- Examination reports and patent prosecution documents (publicly available via IP Australia).
- Patent family data as per WIPO PATENTSCOPE and Espacenet.
- Relevant prior art publications and patents (public domain).
[1] WIPO. Patent scope. (2023).
